Compliance of Familial Mediterranean Fever Patients With Regular Follow-up Visits and Associated Factors.
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
pubmed:
11
12
2020
medline:
28
12
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
Follow-up is crucial to detect asymptomatic complications of familial Mediterranean fever (FMF). The current European League Against Rheumatism recommendations state that patients with FMF should be evaluated at least every 6 months to monitor attacks, acute phase response, and proteinuria. This study aimed to assess compliance of FMF patients with regular follow-up visits and the associated factors. Adult patients with a diagnosis of FMF who had their initial visit at least over 1 year ago were included. Demographic and socioeconomic data, family history, and comorbid diseases were obtained from medical records. The International Severity Score for FMF and the Autoinflammatory Disease Damage Index scores were calculated. We defined patients as "compliant with follow-up visits" both if they had at least 2 visits during the previous year and a compatible physician's assessment. The characteristics of the compliant and noncompliant patients were compared, and multivariable logistic regression analysis was used to determine the factors influencing visit compliance. Four hundred seventy-four patients with FMF were included. Two hundred thirty (48.5%) were compliant, and 244 (51.5%) were noncompliant with follow-up visits. A family history of FMF in parents, the absence of a family history of FMF in siblings, treatment with biologic agents, concomitant medication use, multisite involvement during FMF attacks, and treatment satisfaction were independent predictors of visit compliance. Only half of the patients with FMF were compliant with follow-up visits. Better strategies should be implemented to increase the compliance of FMF patients. Identifying independent predictors would help to build one.
Sections du résumé
BACKGROUND
BACKGROUND
Follow-up is crucial to detect asymptomatic complications of familial Mediterranean fever (FMF). The current European League Against Rheumatism recommendations state that patients with FMF should be evaluated at least every 6 months to monitor attacks, acute phase response, and proteinuria.
OBJECTIVES
OBJECTIVE
This study aimed to assess compliance of FMF patients with regular follow-up visits and the associated factors.
METHODS
METHODS
Adult patients with a diagnosis of FMF who had their initial visit at least over 1 year ago were included. Demographic and socioeconomic data, family history, and comorbid diseases were obtained from medical records. The International Severity Score for FMF and the Autoinflammatory Disease Damage Index scores were calculated. We defined patients as "compliant with follow-up visits" both if they had at least 2 visits during the previous year and a compatible physician's assessment. The characteristics of the compliant and noncompliant patients were compared, and multivariable logistic regression analysis was used to determine the factors influencing visit compliance.
RESULTS
RESULTS
Four hundred seventy-four patients with FMF were included. Two hundred thirty (48.5%) were compliant, and 244 (51.5%) were noncompliant with follow-up visits. A family history of FMF in parents, the absence of a family history of FMF in siblings, treatment with biologic agents, concomitant medication use, multisite involvement during FMF attacks, and treatment satisfaction were independent predictors of visit compliance.
CONCLUSIONS
CONCLUSIONS
Only half of the patients with FMF were compliant with follow-up visits. Better strategies should be implemented to increase the compliance of FMF patients. Identifying independent predictors would help to build one.
Identifiants
pubmed: 33298810
pii: 00124743-202201000-00025
doi: 10.1097/RHU.0000000000001632
doi:
Substances chimiques
Colchicine
SML2Y3J35T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e77-e80Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Manthiram K, Zhou Q, Aksentijevich I, et al. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol . 2017;18:832–842.
Özen S. Update on the epidemiology and disease outcome of familial Mediterranean fever. Best practice & research. Clin Rheumatol . 2018;32:254–260.
Cerrito L, Sicignano LL, Verrecchia E, et al. Epidemiology of FMF Worldwide, in Familial Mediterranean Fever . Berlin, Germany: Springer; 2015. p. 81–90.
Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet . 1998;351:659–664.
Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis . 2019;78:1025–1032.
Atas N, Armagan B, Bodakci E, et al. Familial Mediterranean fever is associated with a wide spectrum of inflammatory disorders: results from a large cohort study. Rheumatol Int . 2020;40:41–48.
Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med . 1986;314:1001–1005.
Ozen S, Bilginer Y, Aktay Ayaz N, et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol . 2011;38:516–518.
Varan O, Kucuk H, Babaoglu H, et al. Chronic inflammation in adult familial Mediterranean fever patients: underlying causes and association with amyloidosis. Scand J Rheumatol . 2019;48:315–319.
Twig G, Livneh A, Vivante A, et al. Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann Rheum Dis . 2014;73:704–709.
Buskila D, Zaks N, Neumann L, et al. Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol . 1997;15:355–360.
Makay B, Kiliçaslan SK, Anik A, et al. Assessment of sleep problems in children with familial Mediterranean fever. Int J Rheum Dis . 2017;20:2106–2112.
Varan O, Kucuk H, Babaoglu H, et al. Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients. Clin Rheumatol . 2019;38:1125–1130.
Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis . 2016;75:644–651.
Babaoglu H, Varan O, Atas N, et al. Detection of familial Mediterranean fever attacks by using a connected activity tracker and assessment of impact of attacks to daily physical activities: a pilot study. Clin Rheumatol . 2019;38:1941–1946.
Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum . 1997;40:1879–1885.
Demirkaya E, Acikel C, Hashkes P, et al. Development and initial validation of International Severity Scoring System for Familial Mediterranean Fever (ISSF). Ann Rheum Dis . 2016;75:1051–1056.
Ter Haar NM, Annink KV, Al-Mayouf SM, et al. Development of the Autoinflammatory Disease Damage Index (ADDI). Ann Rheum Dis . 2017;76:821–830.
Delaney C. Reducing recidivism: medication versus psychosocial rehabilitation. J Psychosoc Nurs Ment Health Serv . 1998;36:28–34.
Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv . 1998;49:196–201.
Ozdogan H, Ugurlu S. Familial Mediterranean fever. Presse Med . 2019;48:e61–e76.
Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med . 1974;291:932–934.
Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum . 2004;33:273–282.
Calligaris L, Marchetti F, Tommasini A, et al. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr . 2008;167:695–696.
Corsia A, Georgin-Lavialle S, Hentgen V, et al. A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet J Rare Dis . 2017;12:54.
Sonmez HE, Esmeray P, Batu ED, et al. Is age associated with disease severity and compliance to treatment in children with familial Mediterranean fever? Rheumatol Int . 2019;39:83–87.